Document is current
Any future updates will be listed below
-
Authors
Kagan, Risa https://orcid.org/0000-0002-6826-0787
Cano, Antonio https://orcid.org/0000-0001-8046-0303
Nappi, Rossella E. https://orcid.org/0000-0003-1713-6396
English, Marci L.
Mancuso, Shayna
Wu, Xi
Ottery, Faith D. https://orcid.org/0000-0002-6295-5166
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04003155 at ClinicalTrials.govnct04003142 at ClinicalTrials.govDocuments that mention this clinical trial
Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data
https://doi.org/10.1007/s12325-024-02849-2
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies
https://doi.org/10.1007/s12325-024-03073-8
Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause
https://doi.org/10.1007/s12325-024-02787-z
▼Fezolinetant for menopausal vasomotor symptoms
https://doi.org/10.1136/dtb.2024.000025
nct04003389 at ClinicalTrials.govDocuments that mention this clinical trial
Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data
https://doi.org/10.1007/s12325-024-02849-2
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies
https://doi.org/10.1007/s12325-024-03073-8
Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause
https://doi.org/10.1007/s12325-024-02787-z
▼Fezolinetant for menopausal vasomotor symptoms
https://doi.org/10.1136/dtb.2024.000025
Documents that mention this clinical trial
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies
https://doi.org/10.1007/s12325-024-03073-8
▼Fezolinetant for menopausal vasomotor symptoms
https://doi.org/10.1136/dtb.2024.000025
-
Funding
Funding for this research was provided by:
Astellas Pharma US
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 18 November 2024
First Online: 30 December 2024
Declarations
:
: RK has received consulting/advisory board fees from Astellas, Pfizer, and Mayne, participated in the data monitoring committee for Astellas (ended), received speaker fees from Pfizer and Astellas, and acted as Medical Advisor for Carrot Fertility. AC acted as former President of the European Menopause and Andropause Society and consulted for Astellas, Theramex, and Viatris. REN received grants from Fidia, consulting fees from Astellas, Besins, Bayer, Exeltis, Fidia, Freya, HRA, Theramex, and Vichy Laboratories, honoraria for lectures from Abbott, Bayer, Exeltis, Novo Nordisk, Organon, Shionogi, Theramex, and Viatris, was a researcher for Fidia, Merck, and Shionogi, and is President Elect of the International Menopause Society. MLE, SM, XW, and FDO are employees of Astellas.
: SKYLIGHT 1, 2, and 4 were conducted in accordance with Declaration of Helsinki, Good Clinical Practice, and International Council for Harmonisation guidelines. An independent ethics committee or institutional review board reviewed ethical, scientific, and medical appropriateness of the study at each site before data collection. Written informed consent was obtained from all participants before any study-related procedures.
